Drug therapy for urinary incontinence

Bailliere's Best Practice and Research in Clinical Obstetrics and Gynaecology

Volumn 14, Issue 2, 2000, Pages 291-313

  Andersson, K E ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Antimuscarinic drugs; Bladder overactivity; Controlled clinical trials; Overflow incontinence; Stress incontinence

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; ESTROGEN; MUSCARINIC RECEPTOR BLOCKING AGENT; OXYBUTYNIN; PROSTAGLANDIN SYNTHASE INHIBITOR;

CENTRAL NERVOUS SYSTEM; CONSTIPATION; DROWSINESS; HUMAN; PRIORITY JOURNAL; REVIEW; STRESS INCONTINENCE; URGE INCONTINENCE; URINE INCONTINENCE; VISUAL IMPAIRMENT; XEROSTOMIA;

EID: 0034130147     PISSN: 15216934     EISSN: None     Source Type: Journal    
DOI: 10.1053/beog.1999.0075     Document Type: Article

References (149)

1. Hunskaar S, Arnold E P, Burgio K. Epidemiology and natural history of urinary incontinence. Abrams P, Khoury S, Wein A. Incontinence, 1st International Consultation on Incontinence. 1999;197-226 Plymbridge Distributors Ltd.
2. Versi E, Defever M, Hu T-W. Socioeconomic consideration. Abrams P, Khoury S, Wein A. Incontinence, 1st International Consultation on Incontinence. 1999;869-892 Plymbridge Distributors Ltd.
3. Thüroff J W, Chartier-Kastler E, Corcus J. Medical treatment and medical side effects in urinary incontinence in the elderly. World Journal of Urology. 16:1998;S48-S61.
4. Andersson K-E, Appell R, Cardozo L. Pharmacological treatment of urinary incontinence. Abrams P, Khoury S, Wein A. Incontinence, 1st International Consultation on Incontinence. 1999;447-486 Plymbridge Distributors Ltd.
5. de Groat W C, Downie J W, Levin R M. Basic neurophysiology and neuropharmacology. Abrams P, Khoury S, Wein A. Incontinence, 1st International Consultation on Incontinence. 1999;105-154 Plymbridge Distributors Ltd.
6. Andersson K-E. Pharmacology of lower urinary tract smooth muscles and penile erectile tissues. Pharmacological Reviews. 45:1993;253-308.
7. Brading A F. A myogenic basis for the overactive bladder. Urology. 50:1997;57-67.
8. de Groat W C. A neurological basis for the overactive bladder. Urology. 50:1997;36-52.
9. Andersson K-E. The overactive bladder: pharmacological basis of drug treatments. Urology. 50:1997;74-84.
10. De Lancey O L, Fowler C J, Keane D. Pathophysiology. Abrams P, Khoury S, Wein A. Incontinence, 1st International Consultation on Incontinence. 1999;227-294 Plymbridge Distributors Ltd.
11. Eglen R M, Hegde S S, Watson N. Muscarinic receptor subtypes and smooth muscle function. Pharmacological Reviews. 48:1996;531-565.
12. Caulfield M P, Birdsall N JM. International Union of Pharmacology: XVII. Classification of muscarinic acetylcholine receptors. Pharmacological Reviews. 50:1998;279-290.
13. Tagliani M, Candura S M, Di Nucci A. A re-appraisal of the nature of the atropine-resistant contraction to electrical field stimulation in the human isolated detrusor muscle. Naunyn-Schmiedeberg's Archives of Pharmacology. 356:1997;750-755.
14. Andersson K-E. The importance of the cholinergic system in neurourology. European Urology. 34:1998;6-9.
15. Hegde S S, Eglen R M. Muscarinic receptor subtypes modulating smooth muscle contractility in the urinary bladder. Life Sciences. 64:1999;419-428.
16. Cardozo L D, Stanton S L. An objective comparison of the effects of parenterally administered drug in patients suffering from detrusor instability. Journal of Urology. 122:1979;58-59.
17. Blaivas J G, Labib K B, Michalik J, Zayed A AH. Cystometric response to propantheline in detrusor hyperreflexia: therapeutic implications. Journal of Urology. 124:1980;259-262.
18. Naglo A S, Nergårdh A, Boréus L O. Influence of atropine and isoprenaline on detrusor hyperactivity in children with neurogenic bladder. Scandinavian Journal of Urology and Nephrology. 15:1981;97-102.
19. Ritch A ES, Castleden C M, George C F, Hall M RP. A second look at emepronium bromide in urinary incontinence. Lancet. i:1977;504-506.
20. Walther S, Hansen J, Hansen L. Urinary incontinence in old age. A controlled trial of emepronium bromide. British Journal of Urology. 54:1982;249-251.
21. Bonnesen T, Tikjøb G, Kamper A L. Effect of emepronium bromide (Cetiprin) on symptoms and urinary bladder function after transurethral resection of the prostate. A double-blind randomized trial. Urologia Internationalis. 39:1984;318-320.
22. Zorzitto M L, Jewett M AS, Fernie G R. Effectiveness of propantheline bromide in the treatment of geriatric patients with detrusor instability. Neurology and Urodynamics. 5:1986;133-140.
23. Andersson K-E. Current concepts in the treatment of disorders of micturition. Drugs. 35:1988;477-494.
24. Wein A J. Pharmacology of incontinence. Urological Clinics of North America. 22:1995;557-577.
25. Smith P H, Cook J B, Prasad E WM. The effect of Ubretid on bladder function after recent complete spinal cord injury. British Journal of Urology. 46:1974;187-192.
26. Wessler I, Kirkpatrick C J, Racke K. Non-neuronal acetylcholine, a locally acting molecule, widely expressed in biological systems: expression and function in humans. Pharmacology and Therapeutics. 77:1998;59-79.
27. Massey J A, Abrams P. Dose titration in clinical trials: an example using emepronium carrageenate in detrusor instability. British Journal of Urology. 58:1986;125-128.
28. Nilvebrant L, Andersson K-E, Gillberg P-G. Tolterodine - a new bladder selective antimuscarinic agent. European Journal of Pharmacology. 327:1997;195-207.
29. Nilvebrant L, Gillberg P G, Sparf B. Antimuscarinic potency and bladder selectivity of PNU-200577, a major metabolite of tolterodine. Pharmacology and Toxicology. 81:1997;169-172.
30. Nilvebrant L, Hallén B, Larsson G. Tolterodine - a new bladder selective muscarinic receptor antagonist: preclinical pharmacological and clinical data. Life Sciences. 60:1997;1129-1136.
31. Stahl M MS, Ekström B, Sparf B. Urodynamic and other effects of tolterodine: a novel antimuscarinic drug for the treatment of detrusor overactivity. Neurourology and Urodynamics. 14:1995;647-655.
32. Brynne N, Dalen P, Alvan G. Influence of CYP2D6 polymorphism on the pharmacokinetics and pharmacodynamics of tolterodine. Clinical Pharmacology and Therapeutics. 63:1998;529-539.
33. Postlind H, Danielson A, Lindgren A, Andersson S H. Tolterodine, a new muscarinic receptor antagonist, is metabolized by cytochromes P450 2D6 and 3A in human liver microsomes. Drug Metabolism and Disposition. 26:1998;289-293.
34. Brynne N, Stahl M MS, Hallén B. Pharmacokinetics and pharmacodynamics of tolterodine in man: a new drug for the treatment of urinary bladder overactivity. International Journal of Clinical Pharmacology and Therapeutics. 35:1997;287-295.
35. Hills C J, Winter S A, Balfour J A. Tolterodine. Drugs. 55:1998;813-820.
36. van Kerrebroeck P E, Amarenco G, Thuroff J W. Dose-ranging study of tolterodine in patients with detrusor hyperreflexia. Neurourology and Urodynamics. 17:1998;499-512.
37. Larsson G, Hallen B, Nilvebrant L. Tolterodine in the treatment of overactive bladder: analysis of the pooled phase II efficacy and safety data. Urology. 53:1999;990-998.
38. Millard R, Tuttle J, Moore K. Clinical efficacy and safety of tolterodine compared to placebo in detrusor overactivity. Journal of Urology. 161:1999;1551-1555.
39. Abrams P, Freeman R, Anderstrom C, Mattiasson A. Tolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladder. British Journal of Urology. 81:1998;801-810.
40. Ekström B, Andersson K-E, Mattiasson A. Urodynamic effects of intravesical instillation of atropine and phentolamine in patients with detrusor hyperactivity. Journal of Urology. 149:1992;155-158.
41. Glickman S, Tsokkos N, Shah P J. Intravesical atropine and suppression of detrusor hypercontractility in the neuropathic bladder. A preliminary study. Paraplegia. 33:1995;36-39.
42. Muskat Y, Bukovsky I, Schneider D, Langer R. The use of scopolamine in the treatment of detrusor instability. Journal of Urology. 156:1996;1989-1990.
43. Coombes G M, Millad R J. Urinary urge incontinence: randomised crossover trials of penthienate versus placebo and propantheline. Medical Journal of Australia. 165:1996;473-476.
44. Stöhrer M, Bauer P, Gianetti B M. Effect of trospium chloride on urodynamic parameters in patients with detrusor hyperreflexia due to spinal cord injuries: a multicentre placebo controlled double-blind trial. Urologia Internationalis. 47:1991;138-143.
45. Madersbacher H, Stöhrer M, Richter R. Trospium chloride versus oxybutynin: a randomized, double-blind, multicentre trial in the treatment of detrusor hyper-reflexia. British Journal of Urology. 75:1995;452-456.
46. Connolly M J, Astridge P S, White E G. Torsades de pointes complicating treatment with terodiline. Lancet. 338:1981;344-345.
47. Stewart D A, Taylor J, Ghosh S. Terodiline causes polymorphic ventricular tachycardia due to reduced heart rate and prolongation of QT interval. European Journal of Clinical Pharmacology. 42:1992;577-580.
48. Douchamps J, Derenne F, Stockis A. The pharmacokinetics of oxybutynin in man. European Journal of Clinical Pharmacology. 35:1988;515-520.
49. Hughes K M, Lang J CT, Lazare R. Measurement of oxybutynin and its N-desethyl metabolite in plasma, and its application to pharmacokinetic studies in young, elderly and frail elderly volunteers. Xenobiotica. 22:1992;859-869.
50. Waldeck K, Larsson B, Andersson K-E. Comparison of oxybutynin and its active metabolite, N-desethyl-oxybutynin, in the human detrusor and parotid gland. Journal of Urology. 157:1997;1093-1097.
51. Smith E R, Wright S E, Aberg G. Comparison of the antimuscarinic and antispasmodic actions of racemic oxybutynin and desethyloxybutynin and their enantiomers with those of racemic terodiline. Drug Research. 48:1998;1012-1018.
52. Nilvebrant L, Sparf B. Dicyclomine, benzhexol and oxybutynin distinguish between subclasses of muscarinic binding sites. European Journal of Pharmacology. 23:1986;133-143.
53. Norhona-Blob L, Kachur J F. Enantiomers of oxybutynin: in vitro pharmacological characterization at M1, M2 and M3 muscarinic receptors and in vivo effects on urinary bladder contraction, mydriasis and salivary secretion in guinea pigs. Journal of Pharmacology and Experimental Therapeutics. 256:1991;562-567.
54. Yarker Y E, Goa K L, Fitton A. Oxybutynin. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in detrusor instability. Drugs and Aging. 6:1995;243-262.
55. Malone-Lee J, Lubel D, Szonyi G. Low dose oxybutynin for the unstable bladder. British Medical Journal. 304:1992;1053.
56. Amarenco G, Marquis P, McCarthy C, Richard F. Qualité de vie des femmes souffrant d'impériosité mictionelle avec ou sans fuites: étude prospective aprés traitement par oxybutinine (1701 cas). Presse Medicale. 27:1998;5-10.
57. Baigrie R J, Kelleher J P, Fawcett D P, Pengelly A W. Oxybutynin: is it safe? British Journal of Urology. 62:1988;319-322.
58. ®). Therapie. 47:1992;389-392.
59. Kasabian N G, Vlachiotis J D, Lais A. The use of intravesical oxybutynin chloride in patients with detrusor hypertonicity and detrusor hyperreflexia. Journal of Urology. 151:1994;944-945.
60. Palmer L S, Zebold K, Firlit C F, Kaplan W E. Complications of intravesical oxybutynin chloride therapy in the pediatric myelomeningocele population. Journal of Urology. 157:1997;638-640.
61. Collas D, Malone-Lee J G. The pharmacokinetic properties of rectal oxybutynin - a possible alternative to intravesical administration. Neurourology and Urodynamics. 16:1997;346-347.
62. Nilsson C G, Lukkari E, Haarala M. Comparison of a 10-mg controlled release oxybutynin tablet with a 5-mg oxybutynin tablet in urge incontinent patients. Neurourology and Urodynamics. 16:1997;533-542.
63. ®oxybutynin for urge urinary incontinence. Journal of Urology. 159:1998;36.
64. Haruno A. Inhibitory effects of propiverine hydrochloride on the agonist-induced or spontaneous contractions of various isolated muscle preparations. Arzneimittel-Forschung/Drug Research. 42:1992;815-817.
65. Tokuno H, Chowdhury J U, Tomita T. Inhibitory effects of propiverine on rat and guinea-pig urinary bladder muscle. Naunyn-Schmiedeberg's Archives of Pharmacology. 348:1993;659-626.
66. Muller C, Siegmund W, Huupponen R. Kinetics of propiverine as assessed by radioreceptor assay in poor and extensive metabolizers of debrisoquine. European Journal of Drug Metabolism and Pharmacokinetics. 18:1993;265-272.
67. Richter, R, Madersbacher, H, Stohrer, M, Double-blind, placebo-controlled clinical study of propiverine in patients suffering from detrusor hyperreflexia, 1997.
68. Wehnert J, Sage S. Comparative investigations to the action of Mictonorm (propiverin hydrochloride) and Spasuret (flavoxat hydrochloride) on detrusor vesicae. Zeitschrift für Urologie und Nephrologie. 82:1989;259-263.
69. ® - eine randomisierte Cross-over-Vergleichsstudie. Aktuelle Urologie. 23:1992;7-11.
70. Madersbacher, H, Halaska, M, Voigt, R, A urodynamic controlled multicenter study in patients with urge incontinence: tolerability and efficacy of propiverine in comparison to oxybutynin, 1997.
71. Guarneri L, Robinson E, Testa R. A review of flavoxate: pharmacology and mechanism of action. Drugs Today. 30:1994;91-98.
72. Oka M, Kimura Y, Itoh Y. Brain pertussis toxin-sensitive G proteins are involved in the flavoxate hydrochloride-induced suppression of the micturition reflex in rats. Brain Research. 727:1996;91-98.
73. Ruffmann R. A review of flavoxate hydrochloride in the treatment of urge incontinence. Journal of International Medical Research. 16:1988;317-330.
74. Briggs K S, Castleden C M, Asher M J. The effect of flavoxate on uninhibited detrusor contractions and urinary incontinence in the elderly. Journal of Urology. 123:1980;665-666.
75. Chapple C R, Parkhouse H, Gardener C, Milroy E JG. Double-blind, placebo-controlled, cross-over study of flavoxate in the treatment of idiopathic detrusor instability. British Journal of Urology. 66:1990;491-494.
76. Dahm T L, Ostri P, Kristensen J K. Flavoxate treatment of micturition disorders accompanying benign prostatic hypertrophy: a double-blind placebo-controlled multicenter investigation. Urologia Internationalis. 55:1995;205-208.
77. Castleden C M, Duffin H M, Gulati R S. Double-blind study of imipramine and placebo for incontinence due to bladder instability. Age and Ageing. 15:1986;299-303.
78. Martin M R, Schiff A A. Fluphenazine/nortriptyline in the irritative bladder syndrome: a double-blind placebo-controlled study. British Journal of Urology. 56:1984;178-179.
79. Lose G, Jorgensen L, Thunedborg P. Doxepin in the treatment of female detrusor overactivity: a randomized double-blind crossover study. Journal of Urology. 142:1989;1024-1026.
80. Miller K, Atkin B, Moody M L. Drug therapy for nocturnal enuresis. Drugs. 44:1992;47-56.
81. Baldessarini K J. Drugs in the treatment of psychiatric disorders. Gilman A D, Goodman L S, Rall T W, Murad F. The Pharmacological Basis of Therapeutics. 1985;387-445 McMillan Publishing Co, London.
82. Maggi C A, Borsini F, Lecci A. The effect of acute and chronic administration of imipramine on spinal and supraspinal micturition reflexes in rats. Journal of Pharmacology and Experimental Therapeutics. 248:1989;278-285.
83. Pairet M, Engelhardt G. Distinct isoforms (COX-1 and COX-2) of cyclooxygenase: possible physiological and therapeutic implications. Fundamental and Clinical Pharmacology. 10:1996;1-17.
84. Cardozo L D, Stanton S L, Robinson H, Hole D. Evaluation of flurbiprofen in detrusor instability. British Medical Journal. 280:1980;281-282.
85. Palmer J. Report of a double-blind crossover study of flurbiprofen and placebo in detrusor instability. Journal of International Medical Research. 11:1993;11-17.
86. Cardozo L D, Stanton S L. A comparison between bromocriptine and indomethacin in the treatment of detrusor instability. Journal of Urology. 123:1980;399-401.
87. Moffat M E, Harlos S, Kirshen A J, Burd L. Desmopressin acetate and nocturnal enuresis: how much do we know? Pediatrics. 92:1993;420-425.
88. Janknegt R A, Zweers H MM, Delaere K PJ. Oral desmopressin as a new treatment modality for primary nocturnal enuresis in adolescents and adults: a double-blind, randomized, multicenter study. Journal of Urology. 157:1997;513-517.
89. Skoog S J, Stokes A, Turner K L. Oral desmopressin: a randomized double-blind placebo controlled study of effectiveness in children with primary nocturnal enuresis. Journal of Urology. 158:1997;1035-1040.
90. Månsson W, Sundin T, Gullberg B. Evaluation of a synthetic vasopressin analogue for treatment of nocturia in benign prostatic hypertrophy. Scandinavian Journal of Urology and Nephrology. 14:1980;139-141.
91. Hilton P, Stanton S L. The use of desmopressin (DDAVP) in nocturnal frequency in the female. British Journal of Urology. 54:1982;252-255.
92. Hilton P, Hertogs K, Stanton S L. The use of desmopressin (DDAVP) for nocturia in women with multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry. 46:1983;854-855.
93. Kinn A-C, Larsson P O. Desmopressin: a new principle for symptomatic treatment of urgency and incontinence in patients with multiple sclerosis. Scandinavian Journal of Urology and Nephrology. 24:1990;109-112.
94. Eckford S D, Swami K S, Jackson S R, Abrams P H. Desmopressin in the treatment of nocturia and enuresis in patients with multiple sclerosis. British Journal of Urology. 74:1994;733-735.
95. Fredrikson S. Nasal spray desmopressin treatment of bladder dysfunction in patients with multiple sclerosis. Acta Neurologica Scandinavica. 94:1996;31-34.
96. Horowitz M, Combs A J, Gerdes D. Desmopressin for nocturnal incontinence in the spina bifida population. Journal of Urology. 158:1997;2267-2268.
97. Robson W L, Nørgaard J P, Leung A K. Hyponatremia in patients with nocturnal enuresis treated with DDAVP. European Journal of Pediatrics. 155:1996;959-962.
98. Schwab M, Ruder H. Hyponatraemia and cerebral convulsion due to DDAVP administration in patients with enuresis nocturna or urine concentration testing. European Journal of Pediatrics. 156:1997;668.
99. Andersson K-E. Clinical pharmacology of potassium channel openers. Pharmacology and Toxicology. 70:1992;244-254.
100. 1-adrenoceptors and uroselectivity. Prostate. 30:1997;202-215.
101. Jensen D. Uninhibited neurogenic bladder treated with prazosin. Scandinavian Journal of Urology and Nephrology. 15:1981;229-233.
102. Petersen T, Husted S, Sidenius P. Prozosin treatment of neurological patients with detrusor hyperreflexia and bladder emptying disability. Scandinavian Journal of Urology and Nephrology. 23:1989;189-194.
103. Åmark P, Nergårdh A. Influence of adrenergic agonists and antagonists on urethral pressure, bladder pressure and detrusor hyperactivity in children with myelodysplasia. Acta Paediatrica Scandinavica. 80:1991;824-832.
104. Jollys J V, Jollys J C, Wilson J. Does sexual equality extend to urinary symptoms? Neurourology and Urodynamics. 12:1993;391-392.
105. Lepor H, Machi G. Comparison of the AUA symptom index in unselected males and females between 55 and 79 years of age. Urology. 42:1993;36-40.
106. Serels S, Stein M. Prospective study comparing hyoscyamine, doxazosin, and combination therapy for the treatment of urgency and frequency in women. Neurourology and Urodynamics. 17:1998;31-36.
107. 3-adrenoceptors. British Journal of Clinical Pharmacology. 43:1996;291-300.
108. Strosberg A D, Pietri-Rouxel F. Function and regulation of the β3-adrenoceptor. Trends in Pharmacological Sciences. 17:1997;373-381.
109. 3-adrenoceptors in the human detrusor. Journal of Urology. 157:1997;175.
110. Igawa Y, Yamazaki Y, Takeda H. Functional and molecular biological evidence for a possible beta3-adrenoceptor in the human detrusor muscle. British Journal of Pharmacology. 126:1999;819-825.
111. Takeda M, Obara K, Mizusawa T. Evidence for β3-adrenoceptor subtypes in relaxation of the human urinary bladder detrusor: analysis by molecular biological and pharmacological methods. Journal of Pharmacology and Experimental Therapeutics. 288:1999;1367-1373.
112. Grüneberger A. Treatment of motor urge incontinence with clenbuterol and flavoxate hydrochloride. British Journal of Obstetrics and Gynaecology. 91:1984;275-278.
113. Castleden C M, Morgan B. The effect of β-adrenoceptor agonists on urinary incontinence in the elderly. British Journal of Clinical Pharmacology. 10:1980;619-620.
114. Steers W D, Meythaler J M, Haworth C. Effects of acute bolus and chronic continuous intrathecal baclofen on genitourinary dysfunction due to spinal cord pathology. Journal of Urology. 148:1992;1849-1855.
115. Bushman W, Steers W D, Meythaler J M. Voiding dysfunction in patients with spastic paraplegia: urodynamic evaluation and response to continuous intrathecal baclofen. Neurourology and Urodynamics. 12:1993;163-170.
116. Taylor M C, Bates C P. A double-blind crossover trial of baclofen - a new treatment for the unstable bladder syndrome. British Journal of Urology. 51:1979;504-505.
117. Maggi C A. The dual, sensory and 'efferent' function of the capsaicin-sensitive primary sensory neurons in the urinary bladder and urethra. Maggi C A. Nervous Control of the Urogenital System. The Autonomic Nervous System. 3:1993;383-422 Harwood Academic Publishers, Chur.
118. Fowler C J, Jewkes D, McDonald W I. Intravesical capsaicin for neurogenic bladder dysfunction. Lancet. 339:1992;1239.
119. Geirsson G, Fall M, Sullivan L. Clinical and urodynamic effects of intravesical capsaicin treatment in patients with chronic traumatic spinal detrusor hypereflexia. Journal of Urology. 154:1995;1825-1829.
120. Chandiramani V A, Peterson T, Duthie G S, Fowler C J. Urodynamic changes during therapeutic intravesical instillations of capsaicin. British Journal of Urology. 77:1996;792-797.
121. Cruz F, Guimaraes M, Silva C. Desensitization of bladder sensory fibers by intravesical capsaicin has long lasting clinical and urodynamic effects in patients with hyperactive or hypersensitive bladder dysfunction. Journal of Urology. 157:1997;585-589.
122. De Ridder D, Chandiramani V, Dasgupta P. Intravesical capsaicin as a treatment for refractory detrusor hyperreflexia: a dual center study with long-term follow up. Journal of Urology. 158:1997;2087-2092.
123. Wiart L, Joseph P A, Petit H. The effects of capsaicin on the neurogenic hyperreflexic detrusor. A double blind placebo controlled study in patients with spinal cord disease. Preliminary results. Spinal Cord. 36:1998;95-99.
124. Dasgupta P, Chandiramani V, Parkinson M C. Treating the human bladder with capsaicin: is it safe? European Urology. 33:1998;28-31.
125. Ishizuka O, Mattiasson A, Andersson K-E. Urodynamic effects of intravesical resiniferatoxin and capsaicin in conscious rats with and without outflow obstruction. Journal of Urology. 154:1995;611-616.
126. Lazzeri M, Beneforti P, Turini D. Urodynamic effects of intravesical resiniferatoxin in humans: preliminary results in stable and unstable detrusor. Journal of Urology. 158:1997;2093-2096.
127. Cruz F, Guimaraes M, Silva C, Reis M. Suppression of bladder hyperreflexia by intravesical resiniferatoxin. Lancet. 350:1997;640-641.
128. Cardozo L, Rekers H, Tapp A. Oestriol in the treatment of postmenopausal urgency: a multicentre study. Maturitas. 18:1993;47-53.
129. Gnad H, Burmucic R, Petritsch P, Steindorfer P. Conservative therapy of female stress incontinence. Double-blind study with the alpha-sympathomimetic midodrin. Fortschritte der Medizin. 102:1984;578-580.
130. Lose G, Lindholm D. Clinical and urodynamic effects of norfenefrine in women with stress incontinence. Urologia Internationalis. 39:1984;298-302.
131. Diokno A C, Taub M. Ephedrine in treatment of urinary incontinence. Urology. 5:1975;624-625.
132. Ek A, Andersson K-E, Gullberg B, Ulmsten U. The effects of long-term treatment with norephedrine on stress incontinence and urethral closure profile. Scandinavian Journal of Urology and Nephrology. 12:1978;105-110.
133. Collste L, Lindskog M. Phenylpropanolamine in treatment of female stress urinary incontinence. Double-blind placebo controlled study in 24 patients. Urology. 40:1987;398-403.
134. Kinn A C, Lindskog M. Estrogens and phenylpropanolamine in combination for stress urinary incontinence in postmenopausal women. Urology. 32:1988;273-280.
135. Ahlström K, Sandahl B, Sjöberg B. Effect of combined treatment with phenylpropanolamine and estriol, compared with estriol treatment alone, in postmenopausal women with stress urinary incontinence. Gynecological and Obstetrical Investigation. 30:1990;37-43.
136. Gilja I, Radej M, Kovacic M, Parazajdes J. Conservative treatment of female stress incontinence with imipramine. Journal of Urology. 132:1984;909-911.
137. 2-adrenergic agonist in stress incontinence. International Urogynecology Journal. 4:1993;146-151.
138. Thor K B, Katofiasc M A. Effects of duloxetine, a combined serotonin and norepinephrine reuptake inhibitor, on central neural control of lower urinary tract function in the chloralose-anesthetized female cat. Journal of Pharmacology and Experimental Therapeutics. 274:1995;1014-1024.
139. Zinner, N, Sarshik, S, Yalcin, I, Efficacy and safety of duloxetine in stress urinary incontinent patients: double blind, placebo-controlled multiple dose study, 1998.
140. Fantl J A, Bump R C, Robinson D. Efficacy of estrogen supplementation in the treatment of urinary incontinence. Obstetrics and Gynecology. 88:1996;745-749.
141. Jackson S, Shepherd A, Abrams P. The effect of oestradiol on objective urinary leakage in postmenopausal stress incontinence; a double blind placebo controlled trial. Neurourology and Urodynamics. 15:1996;322-323.
142. Fantl J A, Cardozo L, McClish D K. Estrogen therapy in the management of urinary incontinence in postmenopausal women: a meta-analysis. First report of the Hormones and Urogenital Therapy Committee. Obstetrics and Gynecology. 83:1994;12-18.
143. Sultana C J, Walters M D. Estrogen and urinary incontinence in women. Maturitas. 20:1990;129-138.
144. Beisland H O, Fossberg E, Moer A, Sander S. Urethral insufficiency in postmenopausal females: treatment with phenylpropanolamine and estriol separately and in combination. Urologia Internationalis. 39:1984;211-216.
145. Hilton P, Tweddel A L, Mayne C. Oral and intravaginal estrogens alone and in combination with alpha adrenergic stimulation in genuine stress incontinence. International Urogynaecology Journal. 12:1990;80-86.
146. Finkbeiner A E. Is bethanechol chlorode clinically effective in promoting bladder emptying: a literature review. Journal of Urology. 134:1985;443-449.
147. Wein A J, Longhurst P A, Levin R M. Pharmacologic treatment of voiding dysfunction. Mundy A R, Stephenson T P, Wein A J. Urodynamics, Principles, Practice, and Application. 1994;43-70 Churchill Livingstone, New York.
148. Sundin T, Dahlström A, Norlén L, Svedmyr N. The sympathetic innervation and adrenoreceptor function of the human lower urinary tract in the normal state and after parasympathetic denervation. Investigative Urology. 14:1977;322-328.
149. Andersson K-E, Ek A, Hedlund H, Mattiasson A. Effects of prazosin on isolated human urethra and in patients with lower motor neuron lesions. Investigative Urology. 19:1981;39-42.